{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:17:52Z","timestamp":1761844672487,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.hoc.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T01:04:43Z","timestamp":1479949483000},"page":"1317-1332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Transformed Lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Mary Ann","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.07.012_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.012_bib2","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/10428194.2013.802313","article-title":"2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papajik","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.07.012_bib7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.07.012_bib8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter's syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/1097-0142(19800701)46:1<118::AID-CNCR2820460120>3.0.CO;2-J","article-title":"Richter's syndrome in chronic lymphocytic leukemia","volume":"46","author":"Foucar","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.012_bib10","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2016.07.012_bib11","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2016.07.012_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2011.060129","article-title":"NOTCH1 mutations in\u00a0+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of\u00a0+12 CLL","volume":"97","author":"Del Giudice","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.07.012_bib14","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.0606108103","article-title":"NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth","volume":"103","author":"Palomero","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2016.07.012_bib15","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.07.012_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A\u00a0phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/1097-0142(19860101)57:1<75::AID-CNCR2820570116>3.0.CO;2-X","article-title":"Prolymphocytic transformation of chronic lymphocytic leukemia. A report of three cases and review of the literature","volume":"57","author":"Ghani","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.012_bib19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.leu.2404183","article-title":"Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation","volume":"20","author":"Reiniger","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.07.012_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.1986.tb07575.x","article-title":"The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation","volume":"64","author":"Melo","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/ajcp\/93.3.333","article-title":"Hodgkin's disease variant of Richter's syndrome. Report of eight cases","volume":"93","author":"Brecher","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2016.07.012_bib23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2016.07.012_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib25","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib26","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib27","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.07.012_bib29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gine","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib31","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib32","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2002-08-2482","article-title":"BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma","volume":"102","author":"Akasaka","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib33","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.012_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.07.012_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2016.07.012_bib39","doi-asserted-by":"crossref","first-page":"e0134833","DOI":"10.1371\/journal.pone.0134833","article-title":"High throughput sequencing analysis of the immunoglobulin heavy chain gene from flow-sorted B cell sub-populations define the dynamics of follicular lymphoma clonal evolution","volume":"10","author":"Carlotti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2016.07.012_bib40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.hoc.2016.07.012_bib41","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.leu.2404696","article-title":"Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma","volume":"21","author":"Fitzgibbon","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.07.012_bib42","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2002-07-2119","article-title":"Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations","volume":"101","author":"Martinez-Climent","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib44","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":"Long-term survival after histologic transformation of low-grade follicular lymphoma","volume":"13","author":"Yuen","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib47","first-page":"1","article-title":"Validation of the NCC-IPI in both de novo and transformed diffuse large B cell lymphoma","author":"Spiegel","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.07.012_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0609.2008.01146.x","article-title":"High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma","volume":"81","author":"Hamadani","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","article-title":"Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma","volume":"113","author":"Chen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/bbmt.1999.v5.pm10465106","article-title":"Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies","volume":"5","author":"Friedberg","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.07.012_bib52","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A\u00a015-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.07.012_bib53","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group","volume":"31","author":"Villa","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib54","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","article-title":"Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma","volume":"20","author":"Wirk","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.07.012_bib55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.012_bib56","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3109\/10428194.2010.497981","article-title":"Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma","volume":"51","author":"Clavert","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.07.012_bib57","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2012.074252","article-title":"Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse","volume":"98","author":"Wartenberg","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.07.012_bib58","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2008-08-174839","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone","volume":"113","author":"Carlotti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib59","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib60","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib61","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2004.06.055","article-title":"Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma","volume":"22","author":"Davies","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib62","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"},{"year":"2015","series-title":"A\u00a0phase 1 study of Venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma","author":"Gerecitano","key":"10.1016\/j.hoc.2016.07.012_bib64"},{"key":"10.1016\/j.hoc.2016.07.012_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib66","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood.V120.21.1643.1643","article-title":"A\u00a0phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL)","volume":"120","author":"Blum","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/R01VXG46MFCDVNHL","article-title":"Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases","volume":"120","author":"Lin","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2016.07.012_bib69","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Bea","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib70","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.012_bib71","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.012_bib72","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.012_bib73","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.MP.0000037310.82136.99","article-title":"Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features","volume":"15","author":"Hao","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hoc.2016.07.012_bib74","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","article-title":"Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases","volume":"25","author":"Camacho","year":"2001","journal-title":"Am J Surg Pathol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:03:42Z","timestamp":1760184222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0889858816301009"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.07.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transformed Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}